Navigation Links
Elbit Imaging Announces Availability of Investor Relations Presentation - Analysis Sources and Uses
Date:8/31/2011

TEL AVIV, Israel, August 31, 2011 /PRNewswire/ --

Elbit Imaging Ltd. (NASDAQ: EMITF) ("Elbit") announced today, that the Company has placed an Investor Relations Presentation relating to its Sources and Uses on the Company's website at: http://www.elbitimaging.com under: "Investor Relations - Company Presentations -Analysis of Sources and Uses."  

About Elbit Imaging Ltd.

Elbit Imaging Ltd. operates in the following principal fields of business: (i) Commercial and Entertainment Centers - Initiation, construction and sale of shopping and entertainment centers and other mixed-use real property projects, predominantly in the retail sector, located in Central and Eastern Europe and in India; (ii) U.S. Real Property - Investment in commercial real property in the United States; (iii) Hotels - Hotel operation and management, primarily in major European cities; (iv) Medical Industries - (a) research and development, production and marketing of magnetic resonance imaging guided focused ultrasound treatment equipment and (b) development of stem cell population expansion technologies and stem cell therapy products for transplantation and regenerative medicine; (v) Residential Projects - Initiation, construction and sale of residential projects and other mixed-use real property projects, predominately residential, located primarily in India and in Eastern Europe; (vi) Fashion Apparel - distribution and marketing of fashion apparel and accessories in Israel; and (vii) Other Activities - (a) venture capital investments; and (b) investments in hospitals and farm and dairy plants in India.


Any forward-looking statements in our releases include statements regarding the intent, belief or current expectations of Elbit Imaging Ltd. and our management about our business, financial condition, results of operations, and its relationship with its employees and the condition of our properties. Words such as "believe," "expect," "intend," "estimate" and similar expressions are intended to identify forward-looking statements but are not the exclusive means of identifying such statements. Actual results may differ materially from those projected, expressed or implied in the forward-looking statements as a result of various factors including, without limitation, the factors set forth in our filings with the Securities and Exchange Commission including, without limitation, Item 3.D of our annual report on Form 20-F for the fiscal year ended December 31, 2010, under the caption "Risk Factors." Any forward-looking statements contained in our releases speak only as of the date of such release, and we caution existing and prospective investors not to place undue reliance on such statements. Such forward-looking statements do not purport to be predictions of future events or circumstances, and therefore, there can be no assurance that any forward-looking statement contained our releases will prove to be accurate. We undertake no obligation to update or revise any forward-looking statements.


For Further Information:



Company Contact:
Dudi Machluf
Chief Executive Officer (Co-CEO)
Tel: +972-3-608-6024
dudim@elbitimaging.com

Investor Contact:
Mor Dagan
Investor Relations
Tel: +972-3-516-7620
mor@km-ir.co.il


'/>"/>
SOURCE Elbit Imaging Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Elbit Imaging Ltd. Announces Second Quarter Results for 2011
2. Elbit Imaging Ltd. Announces Interest Rate for the Next Interest Period for Series B Notes
3. Elbit Imaging Announces Share Purchase Agreement With Enter Holdings
4. Elbit Imaging Announces Insightec Treats First Prostate Cancer Patients in Clinical Trials
5. Elbit Imaging Ltd. Announces First Quarter Results for 2010
6. Elbit Imaging Announces Data Monitoring Committee Recommends Continuation of Phase III Study of StemEx(R), a Cord Blood Stem Cell Product, for Leukemia and Lymphoma
7. Elbit Imaging Announces InSightecs First Non-Invasive Technology for Treatment of Uterine Fibroids Awarded MHLW Approval in Japan
8. Elbit Imaging Ltd. Announces Sale of Plaza Centers Shares
9. Elbit Imaging Ltd. Announces - Swiss Team Uses InSightecs ExAblate(R) 4000 Brain System to Treat Patients With Functional Brain Disorders
10. Pathologists Gather to Focus on Advances in Molecular Testing, Digital Imaging, and Biospecimens
11. Strategic Assessments of Leading North American Diagnostic Imaging Market Players
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ANN ARBOR, Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical ... the precise destruction of targeted tissues, announced three leadership team developments today:   ... Josh Stopek, PhD ... ... Veteran medical device executive ...
(Date:9/18/2017)... 2017 EpiVax, Inc. ("EpiVax") a ... immune engineering, today announced a new NIH-funded ... ... and presents a challenge for traditional flu ... be effective. Using state-of-the-art bioinformatics and molecular modeling methods, ...
(Date:9/12/2017)... MOUNTAIN LAKES, N.J. , Sept. 12, 2017  Consumer reviews ... Embrace Hearing as the number one company for hearing ... Oticon™, ReSound™ and fifteen other brands. ... Embrace Hearing Named #1 by Consumers For Hearing Aids ... Embrace Hearing is an online store that ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and ... explains one of the most popular and least understood books in the Holy Scriptures, ... puzzling descriptions that have baffled scholars for centuries. Many have tossed it off as ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and ... of published author, William Nowers. Captain Nowers and his wife, Millie, have six ... years in the Navy. Following his career as a naval aviator and carrier ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
(Date:10/12/2017)... ... , ... On Saturday, October 21, the Health & Wellness Center at Florida ... money for the American Heart Association Heart Walk. Teams of up to 10 people ... keep their treadmills moving for 5 hours. Treadmills will start at 7:00 p.m. on ...
Breaking Medicine News(10 mins):